Safeguard Insights

January 10, 2014

Tomorrow’s Innovation, Today’s Work at Safeguard

Smart money–capital that flows to the greatest and highest purpose–is always predicated on opportunities of the future, tomorrow’s trends that are difficult to decipher in…

Posted by Stephen T. Zarrilli

January 7, 2014

Point-of-Care Testing gains ground with BD’s acquisition of Alverix

In 2007, Alverix set out to revolutionize point-of-care (POC) testing–medical tests conducted in the doctor’s office, at a patient’s bedside, in a clinic or even…

Posted by Gary J. Kurtzman, MD

Inspired by the past. Motivated for the future. January 6, 2014

Inspired by the past. Motivated for the future.

Over the past 60 years, Safeguard Scientifics has demonstrated an unwavering commitment to innovation, which has ultimately improved people’s quality of life, boosted the economy…

Posted by Stephen T. Zarrilli

December 30, 2013

Internet of Things gets boost with PTC acquisition of ThingWorx

In February 2011—long before the term “Internet of Things” became a hot business buzzword—Safeguard Scientifics saw potential in ThingWorx, the first application platform that lets…

Posted by Erik B. Rasmussen

October 7, 2013

Safeguard Increases Aggregate Partner Company Revenue Guidance for 2013

Safeguard announced that it has increased 2013 aggregate partner company revenue guidance to a range of $285 million to $295 million, up from its initial…

Posted by John E. Shave III

May 17, 2013

How Convertible Debt Deal Further Strengthened Safeguard’s Balance Sheet

Safeguard’s convertible debt deal last November reduced Safeguard’s debt to less than a third of its debt level in 2005 and cut interest rate expenses…

Posted by John E. Shave III

January 18, 2013

The State of Safeguard: Where We’ve Been and Where We’re Going

During my nearly five years at Safeguard, I’ve worked closely with my predecessor, Peter Boni, and the current management team to define our strategy and…

Posted by Stephen T. Zarrilli

October 12, 2012

Anatomy of a Deal: Avid Radiopharmaceuticals

This morning, I presented at the 2012 Annual RBC Biotech Conference, which focused on the “Biotech Success Stories of the [Philadelphia] Region”. I was asked…

Posted by James A. Datin

September 28, 2012

Q&A: Gregg Bienstock, CEO, Lumesis – “Surround Yourself With Experts”

The municipal bond market is a thicket of data that can be outdated and doesn’t conform to a standard format, leaving investment firms to spend…

Posted by Peter J. Boni

Content